

25. (Amended) A motilin receptor antagonist composition containing an effective amount of the compound according to claim 1.

Cancel claims 26 and 27 without prejudice or disclaimer.

REMARKS

Claims 1-25 and 28-34 presently appear in this case. The above amendments to the claims are being made in order to eliminate any properly multiply dependent claims, for the purpose of reducing the filing fee. Please enter this amendment prior to calculation of the filing fee in this case.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with Markings to Show Changes Made."

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant(s)

By:

Roger L. Browdy
Registration No. 25,618

Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528
RFB:nmp/wrd

Version with markings to show changes@

IN THE CLAIMS

13. The compound according to ~~any one of claims 1-~~
~~12~~ claim 1, wherein R₆ in Formula (1) is hydrogen or methyl;
or a hydrate or pharmaceutically acceptable salt thereof.

14. The compound according to ~~any one of claims 1-~~
~~13~~ claim 1, wherein R₇ in Formula (1) is hydrogen or optionally
substituted amino;
or a hydrate or pharmaceutically acceptable salt thereof.

15. The compound according to ~~any one of claims 1-~~
~~14~~ claim 1, wherein R₈ in Formula (1) is hydrogen or methyl;
or a hydrate or pharmaceutically acceptable salt thereof.

16. The compound according to claim 1~~any one of~~
~~claims 1-15~~, wherein R₉ in Formula (1) is methyl, isopropyl,
isobutyl, sec-butyl, tert-butyl, 3-pentyl, neopentyl,
cyclohexyl, phenyl, benzyl, para-hydroxybenzyl,
cyclohexylmethyl or para-fluorobenzyl;
or a hydrate or pharmaceutically acceptable salt thereof.

17. The compound according to ~~any one of claims 1-~~
~~16~~ claim 1, wherein R₁₀ in Formula (1) is hydrogen or methyl;
or a hydrate or pharmaceutically acceptable salt thereof.

18. The compound according to ~~any one of claims 1-~~
~~17~~claim 1, wherein R₁₀ in Formula (1) is hydrogen or methyl;
or a hydrate or pharmaceutically acceptable salt thereof.

19. The compound according to ~~any one of claims 1-~~
~~18~~claim 1, wherein R₁₁ in Formula (1) is methyl, hydroxymethyl,
carbamoylmethyl, methanesulfonylmethyl, ureidemethyl,
sulfamoylaminomethyl, methanesulfonylaminomethyl, carbamoyl,
ethylcarbamoyl, n-propylcarbamoyl, isopropylcarbamoyl,
cyclopropylcarbamoyl, tertbutylcarbamoyl, 2-pyridylcarbamoyl,
methoxycarbamoyl, 2-thiazolyl, 1,3,4-oxadiazol-2-yl, 1,2,4-
oxadiazol-5-yl, 1,3,4-triazol-2-yl, 6-methyl-4-pyrimidinon-2-
yl, methylcarbamoyl, methanesulfonylmethylcarbamoyl,
methoxymethylcarbamoyl, 1-morpholinylcarbonyl, 4-
carboxymethyl-1-piperazinecarbonyl, 4-ethoxycarbonylmethyl-1-
piperazinecarbonyl or 4-methylsulfonyl-1-piperazinecarbonyl;
or a hydrate or pharmaceutically acceptable salt thereof.

20. The compound according to ~~any one of claims 1-~~
~~19~~claim 1, wherein R₁₂ in Formula (1) is hydroxy;
or a hydrate or pharmaceutically acceptable salt thereof.

21. The compound according to ~~any one of claims 1-~~
~~20~~claim 1, wherein R₁₃ in Formula (1) is isopropyl, tert-butyl
(tBu), 1,1-dimethylpropyl or 1,1-dimethyl-2-propenyl;
or a hydrate or pharmaceutically acceptable salt thereof.

In re Appl. MATSUOKA18

24. A medicine containing an effective amount of the compound according to ~~any one of claims 1-23~~claim 1 as an active ingredient.

25. A motilin receptor antagonist composition containing an effective amount of the compound according to ~~any one of claims 1-23~~claim 1.